-
Talin1–Piezo1–YAP Axis Orchestrates Endothelial Inflammation
2026-04-26
This study reveals how Talin1 modulates the Piezo1–YAP signaling pathway to drive calcium-dependent endothelial inflammation, a central process in atherosclerosis. The findings highlight Talin1 as a potential therapeutic target and clarify the molecular events underlying vascular inflammation in disease contexts.
-
SARS-CoV-2 N Protein Impairs GADD34-Mediated Innate Immunity
2026-04-25
This study uncovers a novel mechanism by which the SARS-CoV-2 nucleocapsid protein suppresses the innate immune response. By sequestering GADD34 mRNA into atypical stress granule-like foci, the virus impairs IRF3 activation and interferon signaling, facilitating viral replication and immune evasion.
-
Filipin III in Cholesterol Detection: Protocols & Best Pract
2026-04-24
Filipin III, a polyene macrolide antibiotic, empowers researchers to visualize and quantify membrane cholesterol with unmatched specificity. This article distills current experimental workflows, troubleshooting strategies, and data-driven parameters, translating recent advances in cholesterol homeostasis research into actionable lab protocols.
-
WNT5a/GSK3/β-catenin Axis Regulates FAP Adipogenesis in Musc
2026-04-24
This study uncovers the pivotal role of the WNT5a/GSK3/β-catenin signaling axis in regulating adipogenic differentiation of skeletal muscle fibro/adipogenic progenitors (FAPs). By integrating pharmacological, cytometric, and transcriptomic approaches, the authors highlight how targeted modulation of this pathway restrains pathological fat infiltration and supports muscle regeneration, providing mechanistic insights relevant for muscle disease research.
-
Propidium Iodide: DNA Intercalating Dye for Cell Viability &
2026-04-23
Propidium iodide is a red-fluorescent DNA intercalating dye used to distinguish necrotic or apoptotic cells based on membrane integrity. Its high specificity for non-viable cells underpins its use in cell viability assays, apoptosis detection, and cell cycle analysis. APExBIO provides validated, high-purity PI (SKU B7758) for robust, reproducible research results.
-
Dehydroabietic Acid: Dual PPAR-α/γ Agonist for Metabolic Res
2026-04-23
Dehydroabietic acid is a high-purity, dual PPAR-α/γ agonist that enables precise modulation of lipid metabolism and insulin sensitivity in metabolic disorder research. Its robust solubility and stability parameters, combined with validated biological mechanisms, make it a reliable tool for advanced assay design.
-
Applied Workflows for c-Myc tag Peptide in Immunoassays
2026-04-22
The c-Myc tag Peptide from APExBIO enables precise displacement of c-Myc-tagged fusion proteins, enhancing antibody-based assays for transcription factor studies. This article delivers actionable protocols, troubleshooting steps, and insights on integrating autophagy-centric findings for advanced cell signaling research.
-
Ibotenic Acid (SKU B6246): Reliable NMDA Receptor Agonist in
2026-04-22
This article addresses key challenges in neurodegenerative disease modeling and cell-based assays, highlighting the validated performance of Ibotenic acid (SKU B6246) as a precise NMDA receptor agonist. Scenario-driven Q&A blocks guide researchers through best practices, vendor reliability, and practical optimizations for glutamatergic signaling studies.
-
25-Hydroxycholesterol Drives Immunosuppressive Macrophage Pr
2026-04-21
Xiao et al. reveal how lysosomal 25-hydroxycholesterol (25HC) accumulation in tumor-associated macrophages activates AMPKα via the GPR155-mTORC1 axis, resulting in STAT6 phosphorylation and enhanced immunosuppression. Targeting the CH25H-25HC pathway reprograms macrophages, boosting anti-tumor immunity and synergizing with anti-PD-1 therapy.
-
CF10 and EdU Synergy Drives Telomere Attrition in CRC Cells
2026-04-21
This study uncovers a unique synergistic mechanism in which the fluoropyrimidine polymer CF10 and 5-ethynyl-2′-deoxyuridine (EdU) co-treatment promotes telomere attrition and mitotic catastrophe in colorectal cancer cells. The findings expand current understanding of telomerase-targeted combination therapies and highlight potential strategies for improving cancer cell proliferation inhibition.
-
(-)-Arctigenin as a MEK1 Inhibitor: Precision Workflows in C
2026-04-20
Unlock advanced cancer and inflammation research with (-)-Arctigenin, a high-purity MEK1 inhibitor from APExBIO. This guide details actionable experimental protocols and troubleshooting insights, bridging recent mechanistic discoveries with practical assay optimization.
-
Endothelial STING-JAK1 Signaling: Impacts on Tumor Vasculatu
2026-04-20
This study uncovers how endothelial STING-JAK1 interactions, downstream of type I interferon signaling, promote tumor vessel normalization and potentiate antitumor immune responses. The findings redefine the mechanistic role of STING in tumor endothelium, informing future design and application of STING agonists in cancer therapy.
-
Improving In Vitro Cancer Drug Response: Insights from Schwa
2026-04-19
Schwartz et al. (2022) present a refined framework for evaluating anti-cancer drug responses in vitro by distinguishing between proliferative arrest and cell death. Their work demonstrates that most drugs impact both processes in divergent ways, highlighting the necessity for precise assessment metrics to accurately interpret apoptosis induction in cancer cells.
-
(-)-JQ1: Essential JQ1 Stereoisomer for BET Bromodomain Cont
2026-04-18
(-)-JQ1 stands out as the gold-standard inactive control for dissecting BET bromodomain functions in epigenetics and cancer biology research. This guide details practical workflows, comparative advantages, and troubleshooting strategies that maximize specificity and reproducibility in BRD4-focused assays.
-
Mianserin HCl and DM-β-CD Complexes: Effects on Cytotoxicity
2026-04-17
This study rigorously examines how the methylated cyclodextrin DM-β-CD interacts with Mianserin Hydrochloride (MIA) and alters its cytotoxicity profile. Using calorimetry, spectroscopy, and cell-based assays, it reveals that complexation with DM-β-CD increases, rather than decreases, MIA’s cytotoxicity, challenging previous assumptions and informing future antidepressant research compound optimization.